Press coverage about Depomed (NASDAQ:DEPO) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Depomed earned a news impact score of 0.14 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.9829043921392 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of research firms have weighed in on DEPO. ValuEngine upgraded shares of Depomed from a “sell” rating to a “hold” rating in a research note on Wednesday, August 8th. BidaskClub upgraded shares of Depomed from a “sell” rating to a “hold” rating in a research note on Wednesday, June 13th. Royal Bank of Canada set a $8.00 price objective on shares of Depomed and gave the company a “hold” rating in a research note on Wednesday, August 8th. Finally, Janney Montgomery Scott upgraded shares of Depomed from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.00 to $10.00 in a research note on Monday, July 9th. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $8.67.
Shares of DEPO stock traded up $0.12 during trading hours on Wednesday, reaching $7.30. The company had a trading volume of 940,193 shares, compared to its average volume of 1,300,311. Depomed has a one year low of $4.31 and a one year high of $9.48. The firm has a market capitalization of $461.47 million, a PE ratio of -5.79 and a beta of 1.27. The company has a quick ratio of 0.53, a current ratio of 0.55 and a debt-to-equity ratio of 2.48.
Depomed (NASDAQ:DEPO) last announced its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.03. Depomed had a negative net margin of 9.52% and a negative return on equity of 13.22%. The firm had revenue of $63.27 million during the quarter, compared to analyst estimates of $63.72 million. During the same period in the previous year, the business posted $0.08 earnings per share. The business’s revenue for the quarter was down 37.0% on a year-over-year basis. analysts anticipate that Depomed will post -0.48 earnings per share for the current year.
Depomed Company Profile
Depomed, Inc, a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults.
Recommended Story: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.